Form 4: Agilon Health Director Receives Annual Equity Grant

Director Silvana Battaglia was awarded 2,133 restricted stock units as part of her compensation following a recent 1-for-25 reverse stock split.

Summary

• Director Silvana Battaglia acquired 2,133 restricted stock units (RSUs) on June 2, 2026.
• The RSUs are scheduled to vest in full on June 2, 2027, provided the director remains in service.
• Following this transaction, the reporting person beneficially owns a total of 7,926 shares of common stock.
• The filing confirms a 1-for-25 reverse stock split was executed by the company on March 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, administrative filing. While director equity alignment is positive, the confirmation of a massive 1-for-25 reverse split earlier in the year serves as a reminder of past capital structure challenges.

Positives

• Equity-based compensation aligns the director's interests with those of the long-term shareholders.
• The director continues their service on the board, providing continuity in governance.

Negatives

• The mention of a 1-for-25 reverse stock split on March 30, 2026, typically suggests a significant prior decline in share price to maintain exchange listing requirements.
• The grant results in minor future dilution for existing shareholders upon vesting.

Risks

• The value of the equity grant is subject to market volatility and the company's future performance.
• Vesting is contingent upon the director's continued service through June 2027.

Future Outlook

The director's equity is set to vest in mid-2027, indicating a commitment to the company's oversight for at least the next twelve months.

Management Comments

• The restricted stock units vest in full on June 2, 2027, subject to continued service as a director.
• The amount of securities beneficially owned reflects the 1 for 25 reverse stock split effective March 30, 2026.

Industry Context

StockSavvy.ai notes that agilon health's use of equity grants for directors is standard practice in the healthcare services sector to ensure board members have 'skin in the game,' though the recent heavy reverse split suggests the company has faced significant valuation headwinds compared to peers.

Comparison to Industry Standards

• The grant size is consistent with director compensation packages at mid-cap healthcare companies.
• The 1-for-25 reverse split is more aggressive than typical 1-for-5 or 1-for-10 splits seen in the S&P Healthcare Services index, indicating more severe historical price pressure.

Corporate Governance

Related Party Transactions

• Issuance of equity compensation to Director Silvana Battaglia.

Stakeholder Impact

• Shareholders may see minor dilution upon the vesting of these units in 2027.
• The board maintains its current composition, providing stability for employees and partners.

Next Steps

• Full vesting of the 2,133 RSUs on June 2, 2027.

Key Dates

Recommendation

This is a routine Form 4 filing for director compensation. It does not provide new material information regarding the company's operations or financial health beyond confirming the previously executed reverse split and standard board maintenance.

Keywords

agilon health, AGL, Restricted Stock Units, Insider Trading, Director Compensation, Reverse Stock Split, Silvana Battaglia